Related Experiment Video
Updated: Jun 7, 2026
11:15
Next Generation Sequencing for the Detection of Actionable Mutations in Solid and Liquid Tumors
Published on: September 20, 2016
Potential pitfalls in MitoChip detected tumor-specific somatic mutations: a call for caution when interpreting
Malliya Gounder Palanichamy1, Ya-Ping Zhang
1Laboratory for Conservation and Utilization of Bio-resources, Yunnan University, 2 North Green Lake Street, Kunming 650091, China. empalani@yahoo.com
BMC Cancer
|November 2, 2010
Summary
Mitochondrial DNA (mtDNA) mutations linked to cancer may be artifacts of artificial recombination, not true tumor markers. Careful sample handling and evolutionary analysis are crucial for reliable cancer diagnosis using mtDNA data.
Area of Science:
- Genomics
- Cancer Research
- Evolutionary Biology
Background:
- High-throughput mitochondrial sequencing (MitoChip) has identified somatic mtDNA mutations linked to various cancers.
- However, potential pitfalls in detecting tumor-specific mutations necessitate caution in interpreting clinical mtDNA data.
- This study evaluates mitochondrial sequence variants in cancer patients to assess their reliability for early cancer diagnosis.
Purpose of the Study:
- To examine mitochondrial sequence variants in cancer patients.
- To assess the reliability of using detected patterns of polymorphisms for early cancer diagnosis.
- To investigate potential artifacts in tumor-specific somatic mutation detection.
Main Methods:
- Phylogenetic analysis of whole mitochondrial genomes from various cancer types (head and neck, adenoid cystic carcinoma, sessile serrated adenoma, lung).
- Comparison of patient tumor and control leukocyte mtDNA sequences with known population mutations.
- Examination of artificial recombination events and mixed ancestries in single individuals.
Main Results:
- Phylogenetic analysis confirmed artificial recombination events in studies of multiple cancer types.
- Clear evidence of mixed ancestries within single individuals was observed in tumor and control mtDNA haplotype sequences.
- The reliability of detected mtDNA polymorphisms as early cancer diagnostic markers is questioned due to these findings.
Conclusions:
- Clinical and research settings require enhanced care in maintaining sample identity.
- Analysis must consider all available data within an evolutionary framework to eliminate artifacts and mix-ups.
- Accurate interpretation of mtDNA data is essential for reliable cancer diagnosis and patient care.
Related Concept Videos
01:20Mismatch Repair
Organisms are capable of detecting and fixing nucleotide mismatches that occur during DNA replication. This sophisticated process requires identifying the new strand and replacing the erroneous bases with correct nucleotides. Mismatch repair is coordinated by many proteins in both prokaryotes and eukaryotes.
The Mutator Protein Family Plays a Key Role in DNA Mismatch Repair
The human genome has more than 3 billion base pairs of DNA per cell. Prior to cell division, that vast amount of genetic...
The Mutator Protein Family Plays a Key Role in DNA Mismatch Repair
The human genome has more than 3 billion base pairs of DNA per cell. Prior to cell division, that vast amount of genetic...
02:21Cancers Originate from Somatic Mutations in a Single Cell
Cancer arises from mutations in the critical genes that allow healthy cells to escape cell cycle regulation and acquire the ability to proliferate indefinitely. Though originating from a single mutation event in one of the originator cells, cancer progresses when the mutant cell lines continue to gain more and more mutations, and finally, become malignant. For example, chronic myelogenous leukemia (CML) develops initially as a non-lethal increase in white blood cells, which progressively...
02:21Cancers Originate from Somatic Mutations in a Single Cell
Cancer arises from mutations in the critical genes that allow healthy cells to escape cell cycle regulation and acquire the ability to proliferate indefinitely. Though originating from a single mutation event in one of the originator cells, cancer progresses when the mutant cell lines continue to gain more and more mutations, and finally, become malignant. For example, chronic myelogenous leukemia (CML) develops initially as a non-lethal increase in white blood cells, which progressively...